8 opinion
➠
Biochemical and cellular screening along with the The benefits of centralisation are better realised and
data management infrastructure offers pharmaceutical further enhanced when implementing a purpose-built,
organisations clear benefits. Being able to turn data highly configurable LIMS for discovery and research, such
around faster and test across multiple targets, scientists as Nautilus LIMS. Organisations can take advantage of
can prevent the the inherent
progression of capability of
inappropriate
“The centralisation of
the system
chemical (together with
series, identify
biochemical screening
the option to
unexpected
can accelerate decision-
further extend
leads and
making in early drug
functionality
ultimately using industry
Roger Clark
accelerate discovery. Improved data
Trish Meek
standard
the research
turnaround can be addressed with the
programming
on promising languages)
compounds.
deployment of a laboratory information
to grow with
Additionally,
management system (LIMS) as part of a
and adapt
centralisation
centralisation strategy."
to emerging
provides the business
ability for more needs. u
flexible use
of resources, allowing a rapid, immediate response to Roger Clark is a Senior Scientist within the Cancer & Infection
changing business demands. It also enables best practices Department at AstraZeneca, Macclesfield, Cheshire, UK.
to be employed across assay delivery since the number Trish Meek is Director of Product Strategy, Life Sciences at
of different teams generating data is reduced. As a Thermo Fisher Scientific, Philadelphia, PA, USA.
consequence, consistency is increased. www.thermo.com/informatics
Microdosing gaining acceptance
M
icrodosing or phase 0 clinical testing should see a number of opportunities being Meanwhile, early detection is the key
has been gaining acceptance and investigated. focus of cancer diagnostics. traditional
might become an imperative phase of the consolidation within the cro space testing methods such as immunoassay
drug development process in the years to has led to concerns over the quality of testing are facing fierce competition
come. the emergence of niche capability service and attention to detail. companies from evolving segments such as nucleic
providers in preclinical testing and must however ensure the quality of their acid amplification technology (nat) and
technology dependence is also expected services to maintain their bargaining power immunohistochemistry testing. the ability
to result in numerous partnerships and with the pharmaceutical companies to prove the clinical utility and practical
alliances, fuelling growth opportunities in “cros face the challenge of use of the test within a laboratory is one of
this sector. competitively aligning their services to the essential requirements to be successful
“there is every reason to believe meet customer needs in order to overcome in this market.
that the solution for faster screening the threat of losing their stronghold and new analysis from Frost & sullivan,
of candidates and increasing pressure loyalty,” comments sriram european cancer iVd Market, finds that the
on costs is gaining momentum in the developing the technological know-how market earned revenues of $623.5 million
right direction,” says Frost & sullivan and expertise on niche capabilities will in 2008 and estimates this to reach
senior research analyst V sriram. “the help cros retain their client base. this can $1.5 billion in 2015.
compelling advantages of microdosing be achieved in-house or by partnerships the increased prevalence of cancer
present it as a potential remedy for big with pioneers in the provision of niche has resulted in the development of novel
pharma’s maladies regarding declining capability, allowing for the creation of a technologies that support the effective
returns from investments in drug one-stop shop solution. diagnosis of cancer.
development.” strategic analysis of opportunities in rising awareness, paralleled by the
alliances between contract research the cro Market - phase 0 is part of the mounting use of cancer screening tests will
organisations (cros) in the Us and europe pharmaceuticals & Biotechnology growth promote the growth of the european cancer
have not historically been common. this partnership service programme, which also iVd market over the long term. u
is due to several factors including the includes research in the following markets:
industry’s strong growth and relatively low european Biosimilars Market outlook, For more information, visit
technology demands for clinical testing. european Vaccines Market, U.s. contract www.pharma.frost.com or
However, developments in microdosing research outsourcing Markets. www.drugdiscovery.frost.com
www.scientistlive.com
Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44